Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & Toxicity

CD19 CAR-T therapy has revolutionized the management of high risk& relapsed/refractory (R/R) large B-cell lymphoma (LBCL) but remains limited by significant toxicities. In the absence of head-to-head randomized clinical trial data, we evaluated the impact of CAR-T product type on the outcomes of LBCL patients (pts) receiving liso-cel or axi-cel per standard of care.All LBCL pts treated at our center with liso-cel or axi-cel outside of a clinical trial between 1/2018& 6/2023 were included. Best response was determined within 3 months of CAR-T infusion by PET-CT imaging (Lugano 2014 criteria).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Andrew J. Portuguese, Aya Albittar, Jennifer J. Huang, Emily C. Liang, Natalie Wuliji, Mahnoosh Taheri, Alexandre V Hirayama, Erik L. Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Hans-Peter Kiem, Filippo Milano, Aude Tags: 249 Source Type: research